Literature DB >> 3028896

Hepatic estrogen receptor in human liver disease.

L E Porter, M S Elm, D H Van Thiel, P K Eagon.   

Abstract

Human liver contains estrogen receptors which render it sensitive to estrogen. Specific hormone binding to cytosol and nuclei from normal liver containing such receptors is of high affinity, low capacity, saturable, and specific for steroidal and nonsteroidal estrogens. Although estrogens alter metabolism and may produce disease, little data is available concerning estrogen receptor levels found in diseased liver. Herein we report estrogen receptor levels in human female liver containing diseases associated with oral contraceptives. Binding studies demonstrated cytosolic and nuclear estrogen receptors in human hepatic adenoma and focal nodular hyperplasia. Nuclear estrogen receptor levels in neoplastic tissue were greater than those in normal tissue. In addition, one hepatic adenoma resected from a patient taking tamoxifen contained no cytosolic estrogen receptor, and nuclear estrogen receptor levels were significantly lower than those found in normal tissue. These differences in binding capacity suggest a potential for greater hormone responsiveness in neoplastic liver tissue.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028896     DOI: 10.1016/0016-5085(87)90026-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Oestrogen hormone receptors in focal nodular hyperplasia.

Authors:  Manju D Chandrasegaram; Ali Shah; John W Chen; Andrew Ruszkiewicz; David S Astill; Georgina England; Ravish S Raju; Eu Ling Neo; Paul M Dolan; Chuan Ping Tan; Mark Brooke-Smith; Tom Wilson; Robert T A Padbury; Christopher S Worthley
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

Review 2.  Hepatic regeneration. Effects of age, sex hormone status, prolactin, and cyclosporine.

Authors:  D H Van Thiel; R Stauber; J S Gavaler; A Francavilla
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

3.  The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro.

Authors:  A Francavilla; L Polimeno; A DiLeo; M Barone; P Ove; M Coetzee; P Eagon; L Makowka; G Ambrosino; V Mazzaferro
Journal:  Hepatology       Date:  1989-04       Impact factor: 17.425

4.  Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. An association with focal nodular hyperplasia (FNH) and uterine leiomyoma.

Authors:  W H Marks; N Thompson; H Appleman
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

5.  Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats.

Authors:  I Shimizu; M Yasuda; Y Mizobuchi; Y R Ma; F Liu; M Shiba; T Horie; S Ito
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

6.  Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.

Authors:  A Francavilla; A Di Leo; P K Eagon; L Polimeno; F Guglielmi; G Fanizza; M Barone; T E Starzl
Journal:  Gastroenterology       Date:  1987-10       Impact factor: 22.682

Review 7.  Hepatobiliary complications of oral contraceptives.

Authors:  M C Lindberg
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

8.  Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver.

Authors:  P K Eagon; A Francavilla; A DiLeo; M S Elm; L Gennari; V Mazzaferro; G Colella; D H Van Thiel; T E Strazl
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

9.  Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma.

Authors:  F Farinati; N De Maria; A Fornasiero; M Salvagnini; S Fagiuoli; M Chiaramonte; R Naccarato
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

Review 10.  Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.

Authors:  Mamta Kalra; Jary Mayes; Senait Assefa; Anil-K Kaul; Rashmi Kaul
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.